4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Completed · Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction and ease symptoms caused by primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of 4'-iodo-4'-deoxydoxorubicin in treating patients who have primary systemic amyloidosis.

Key facts

Study ID

NCT00003853

Run by

National Cancer Institute (NCI)

People needed

45

Starts

1999-04-01

Expected to finish

2001-08-01

Last updated by the study team

2012-11-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• University of Pavia — Pavia, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.